The present application relates to pharmaceutical compositions and methods for treatment of urogenital diseases and bone metastasis in a human, which pharmaceutical composition contains an effective amount of arsenous acid alkaline or earth alkaline metal salt and/or a pharmaceutically acceptable adjuvant. According to the present invention, the alkaline arsenous acid metal salt is sodium meta-arsenita (AsO2Na) or potassium meta-arsenite (AsO2K). The effective amount of arsenous acid alkaline or earth alkaline metal salt is 0.0001-1500 mg/kg, preferably 1-1000 mg/kg, more preferably 1-150 mg/kg, and most preferably 50-100 mg/kg of body weight/day. The administration form of the pharmaceutical compositions of the invention is preferably oral, such as a tablet, capsule, powder and/or solution with a pharmaceutically acceptable carrier, diluent or excipient.本申請案係關於用於治療人類泌尿生殖器疾病及骨轉移之醫藥組合物及方法，該醫藥組合物包含一有效量之亞砷酸鹼金屬鹽或鹼土金屬鹽及/或一醫藥上可接受佐劑。根據本發明，該鹼金屬亞砷酸鹽係偏亞砷酸鈉(AsO2Na)或偏亞砷酸鉀(AsO2K)。該有效量之亞砷酸鹼金屬鹽或鹼土金屬鹽為0.0001至1500毫克/公斤，較佳為1至1000毫克/公斤，更佳為1至150毫克/公斤，且最佳為50至100毫克/公斤體重/天。本發明醫藥組合物之投藥形式較佳係經口投與，例如具有醫藥上可接受之載劑、稀釋劑或賦形劑之錠劑、膠囊、粉劑及/或溶液。
